← All trials
NCT06236165
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 14, 2024
- Primary completion
- Aug 31, 2024
- Completion date
- Feb 28, 2025
- First posted
- Feb 1, 2024
- Last posted
- Feb 15, 2024
- Enrollment
- 66
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tanta UniversityLead sponsor
- Tanta UniversitySponsor investigator
- Tanta UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.